Darin J. Weber Sells 84,103 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 84,103 shares of the business’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $1.73, for a total transaction of $145,498.19. Following the sale, the senior vice president now directly owns 189,670 shares of the company’s stock, valued at approximately $328,129.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

ProKidney Stock Up 1.1 %

PROK stock traded up $0.03 during mid-day trading on Wednesday, hitting $2.75. The company had a trading volume of 3,070,453 shares, compared to its average volume of 635,572. The company has a market capitalization of $630.69 million, a price-to-earnings ratio of -5.18 and a beta of 1.08. ProKidney Corp. has a 12-month low of $1.12 and a 12-month high of $13.51. The company has a 50-day moving average price of $1.53 and a 200 day moving average price of $1.80.

ProKidney (NASDAQ:PROK) last announced its earnings results on Thursday, March 21st. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.10. As a group, analysts expect that ProKidney Corp. will post -0.65 EPS for the current year.

Hedge Funds Weigh In On ProKidney

Hedge funds have recently added to or reduced their stakes in the company. Barclays PLC grew its stake in ProKidney by 355.2% in the 4th quarter. Barclays PLC now owns 61,815 shares of the company’s stock worth $110,000 after acquiring an additional 48,234 shares in the last quarter. Federated Hermes Inc. raised its holdings in shares of ProKidney by 10,984.7% in the fourth quarter. Federated Hermes Inc. now owns 113,286 shares of the company’s stock worth $202,000 after buying an additional 112,264 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of ProKidney by 174.2% in the fourth quarter. SG Americas Securities LLC now owns 46,829 shares of the company’s stock worth $83,000 after acquiring an additional 29,749 shares during the period. Vanguard Group Inc. increased its holdings in ProKidney by 7.5% in the third quarter. Vanguard Group Inc. now owns 3,291,859 shares of the company’s stock valued at $15,077,000 after buying an additional 229,078 shares in the last quarter. Finally, Tudor Investment Corp Et Al purchased a new position in ProKidney in the third quarter valued at $141,000. 51.59% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

PROK has been the subject of a number of recent research reports. Bank of America downgraded shares of ProKidney from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Morgan Stanley began coverage on shares of ProKidney in a research note on Thursday, March 7th. They set an “equal weight” rating and a $3.00 target price on the stock.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.